Package-Ref? MRD Cocktail Reference Standard
CBP90040
詢 價
索取COA
產(chǎn)品描述
產(chǎn)品數(shù)據(jù)庫
| Introduction | |||||
| Descripition | MRD是指治療后體內(nèi)殘留的腫瘤細胞或者標(biāo)志物，通常的翻譯有3種，微小殘留病灶（Minimal Residual Disease）、可檢測殘留病灶（Measurable Residual Disease）、分子殘留病灶（Molecular Residual Disease）。 | ||||
| 產(chǎn)品說明 | |||||
| 貨號 | 名稱 | %AF | 規(guī)格 | 濃度 | 備注 |
| CBP90040-1 | Package-RefTM MRD Cocktail Reference Standard-0.5% | 0.50% | 500 ng/vial | 20 ng/µL | Optimized ddPCR assay |
| CBP90040-2 | Package-RefTM MRD Cocktail Reference Standard-0.05% | 0.05% | 500 ng/vial | 20 ng/µL | Dilution fold-confirmation |
| CBP90040-3 | Package-RefTM MRD Cocktail Reference Standard-0.005% | 0.005% | 500 ng/vial | 20 ng/µL | Dilution fold-confirmation |
| CBP90040-4 | Package-RefTM MRD Cocktail Reference Standard-0% | 0.00% | 500 ng/vial | 20 ng/µL | ddPCR assay |
| MRD-0.5% ctDNA | |||||
| GENE | Mut. | CDS change | Variant Classification | AF% | |
| EGFR | p.E746_A750delELREA | c.2236_2250del15 GAATTAAGAGAAGCA>- |
Pathogenic | 0.69 | |
| EGFR | p.S768I | c.2303G>T | Pathogenic | 0.61 | |
| EGFR | p.L861Q | c.2582T>A | Pathogenic | 0.61 | |
| ERBB2 | p.A775_G776insYVMA | c.2324_2325ins12 ATACGTGATGGC |
Pathogenic | 0.41 | |
| KRAS | p.G12V | c.35G>T | Pathogenic | 0.39 | |
| PIK3CA | p.E542K | c.1624G>A | Pathogenic | 0.62 | |
| KRAS | p.Q61H | c.183A>C | Pathogenic | 0.49 | |
| EGFR | p.G719C | c.2155G>T | Pathogenic | 0.5 | |
| ROS1 | CD74-ROS1 | chr5:149783684:- (hg19) chr6:117646732:- (hg19) |
Pathogenic | 0.55 | |
| NRAS | p.Q61K | c.181C>A | Pathogenic | 0.41 | |
| IDH1 | p.R132C | c.394C>T | Pathogenic | 0.43 | |
| FBXW7 | p.R505C | c.1513C>T | Pathogenic | 0.75 | |
| KMT2C | p.F4496Lfs*21 | c.13488delA | Likely Pathogenic | 0.46 | |
| RAC1 | p.N92I | c.275A>T | Pathogenic | 0.4 | |
| BCOR | p.Q1321* | c.3961C>T | Likely Pathogenic | 0.68 | |
| BRCA2 | p.M784V | c.2350A>G | Benign | 0.64 | |
| ARID1A | p.G1848Wfs*6 | c.5540dupG | Likely Pathogenic | 0.61 | |
| CDH1 | p.P126Rfs*89 | c.377delC | Pathogenic | 0.74 | |
| BARD1 | p.K208Rfs*4 | c.623delT | Likely Pathogenic | 0.38 | |
| BAX | p.E41Rfs*19 | c.121delG | Pathogenic | 0.75 | |
| NBN | p.R466Gfs*18 | c.1396delT | Pathogenic | 0.71 | |
| KMT2D | p.Q809Rfs*121 | c.2425delG | Likely Pathogenic | 0.51 | |
| KMT2D | p.P647Hfs*283 | c.1940delG | Pathogenic | 0.44 | |
| QKI | p.K134Rfs*14 | c.401delA | Likely Pathogenic | 0.63 | |
| KMT2B | p.W336* | c.1007G>A | Likely Pathogenic | 0.75 | |
| NSD1 | p.M1531Cfs*43 | c.4591delA | Likely Pathogenic | 0.74 | |
| AXIN1 | p.E31* | c.91G>T | Likely Pathogenic | 0.66 | |
| AXIN1 | p.G508Vfs*197 | c.1523del | Likely Pathogenic | 0.69 | |
| ARID1B | p.A547Sfs*35 | c.1638_1647del GGGCGGCGGC |
Pathogenic | 0.47 | |
| HLA-C | p.V100Efs*38 | c.299_300delTG | Likely Pathogenic | 0.51 | |
| TP53BP1 | p.R1447Efs*36 | c.4339delC | Likely Pathogenic | 0.57 | |
| POLD1 | N/A | c.E24-2AG>A | Likely Pathogenic | 0.73 | |
| CYLD | p.N722Mfs*13 | c.2165delA | Likely Pathogenic | 0.57 | |
| INHA | p.G66Afs*61 | c.197delG | Likely Pathogenic | 0.74 | |
| RASA1 | p.N838Mfs*4 | c.2513delA | Likely Pathogenic | 0.51 | |
| RECQL4 | p.G952Afs*92 | c.2855delG | Likely Pathogenic | 0.54 | |
| BRAF | p.V600E | c.1799T>A | Pathogenic | 5.33 | |
| ACVR2A | p.K437Rfs*5 | c.1310delA | Likely Pathogenic | 3.98 | |
| PIK3CA | p.H1047R | c.3140A>G | Pathogenic | 2.81 | |
| BRCA1 | p.D435Y | c.1303G>T | Uncertain significance | 2.53 | |
| BRCA2 | p.N1784Tfs*7 | c.5351delA | Pathogenic | 2.35 | |
| BRCA2 | p.E2292A | c.6875A>C | Uncertain significance | 1.35 | |
| TP53 | N/A | c.783-2A>C | Pathogenic | 1.02 | |
| CDKN2A | p.R80* | c.238C>T | Pathogenic | 0.92 | |
| HLA-A | p.R45Afs*32 | c.133del | Likely Pathogenic | 1.25 | |
| 稀釋倍數(shù)驗證數(shù)據(jù) | |||||
| GENE | Mutation | AF% of MRD-0.5% ctDNA | AF% of MRD-0.05% ctDNA | AF% of MRD-0.005% ctDNA | |
| BRAF | p.V600E | 5.33 | 0.54 | 0.047 | |
| ACVR2A | p.K437Rfs*5 | 3.98 | 0.40 | 0.038 | |
| PIK3CA | p.H1047R | 2.81 | 0.26 | N/A | |
| BRCA1 | p.D435Y | 2.53 | 0.24 | N/A | |
| BRCA2 | p.N1784Tfs*7 | 2.35 | 0.23 | N/A | |
| BRCA2 | p.E2292A | 1.35 | 0.14 | N/A | |
| TP53 | c.783-2A>C | 1.02 | 0.11 | N/A | |
| CDKN2A | p.R80* | 0.92 | 0.10 | N/A | |
| HLA-A | p.R45Afs*32 | 1.25 | 0.11 | N/A | |
|
Product Information |
|||||
| Intended Use | Research Use Only | ||||
| Unit Size | 4支/套，0.5μg/支，20ng/μL | ||||
| Storage | -20℃ | ||||
| Expiry | 36 months from the date of manufacture | ||||
